Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 5, 2011, Pages 339-343

  Dalgic, Nazan ^a   Sancar, Mesut ^b   Bayraktar, Banu ^a   Dincer, Emre ^a   Pelit, Suleyman ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Ertapenem; ESBL; paediatric; urinary tract infection

Indexed keywords

ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE;

ADOLESCENT; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CHILD; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; MALE; PYELONEPHRITIS; TREATMENT INDICATION; URINARY TRACT INFECTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DISK DIFFUSION ANTIMICROBIAL TESTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS; HUMANS; INFANT; MALE; PYELONEPHRITIS; RECURRENCE; RETROSPECTIVE STUDIES; TURKEY; URINARY TRACT INFECTIONS;

EID: 79954550031     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.553241     Document Type: Article

References (29)

1. Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005;18:417-22. (Pubitemid 40548299)
2. American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. Pediatrics 1999;103:843-52.
3. Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum betalactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2008;27:85-8. (Pubitemid 350197875)
4. Cormican M, Morris D, Corbett-Feeeney G, Flynn J. Extended spectrum beta-lactamase production and fluoroquinolone resistance in pathogens associated with community-acquired urinary tract infection. Diagn Microbiol Infect Dis 1998;32:317-9. (Pubitemid 29062882)
5. Arpin C, Dubois V, Coulange L. Extended-spectrum betalactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003;47:3506-14. (Pubitemid 37345711)
6. Lescure FX, Eveillard M, Douadi Y, Eb F. Communityacquired multiresistant bacteria: an emerging problem? J Hosp Infect 2001;49:149-51. (Pubitemid 32982694)
7. Rodrí guez-Bañ o J, Navarro MD, Romero L. Epidemiology and clinical features of infections caused by extendedspectrum beta-lactamase- producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-94. (Pubitemid 38332830)
8. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004;54:735-43. (Pubitemid 39386725)
9. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum betalactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-9. (Pubitemid 41418336)
10. St ü renburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003;47:273-95. (Pubitemid 37322047)
11. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913-20. (Pubitemid 47617735)
12. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrumbeta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:1987-94. (Pubitemid 46903084)
13. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging publichealth concern. Lancet Infect Dis 2008;8:159-66. (Pubitemid 351249250)
14. Elliott E, Brink AJ, van Greune J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006;42:e95 - 8.
15. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
16. Food and Drug Administration Center for Drug Evaluation and Research. Pediatric exclusivity labeling charges. US FDA; 2005. Available at: Http://www.fda.gov/scienceResearch/ specialTopics/PediatricTherapeuticsResearch/ UCM107519. htm (accessed 5 December 2006).
17. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005;65: 2151-78. (Pubitemid 41478796)
18. Hengstler KA, Hammann R, Fahr AM. Evaluation of BBL CHROMagar orientation medium for detection and presumptive identification of urinary tract pathogens. J Clin Microbiol 1997;35:2773-7. (Pubitemid 27452407)
19. National Committee for Clinical Laboratory Standards. Methods for disk susceptibility tests for bacteria that grow aerobically. 7th ed. NCCLS Document M2-A7. Wayne, PA: NCCLS; 2000.
20. Vranes J, Marijan T, Bedenic B, Mlinaric-Dzepina A, Katic S, Kalenic S. Clonal dissemination of highly virulent extendedspectrum beta-lactamase- producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region. Int J Antimicrob Agents 2008;31:S19 - 24.
21. Daza R, Guti é rrez J, Pi é drola G. Antibiotic susceptibility of bacterial strains isolated from patients with communityacquired urinary tract infections. Int J Antimicrob Agents 2001;18:211-5. (Pubitemid 32979192)
22. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163-7. (Pubitemid 38471420)
23. Sorl óz ano A, Gutié rrez J, Romero JM, de Dios Luna J, Damas M, Pi é drola G. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 2007;47:413-6. (Pubitemid 350003894)
24. Arguedas A, Cespedes J, Botet FA, Blumer J, Yogev R, Gesser R, et al. Protocol 036 Study Group. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. Int J Antimicrob Agents 2009;33:163-7.
25. Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, et al. In vitro suscep ibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-73. (Pubitemid 40883183)
26. Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, et al. Protocol 021 Study Group. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 2002;60:16-22. (Pubitemid 34722938)
27. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A; Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34:1076-83. (Pubitemid 34289680)
28. Vetter N, Cambronero-Hernandez E, Rohlf J, Simons S, Carides A, Oliveria T, et al. Protocol 020 Study Group. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002;24:1770-85. (Pubitemid 35440949)
29. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al. Protocol 017 Study Group. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-45. (Pubitemid 38173251)